As Covid drug cash dwindles, Vigonvita targets new remedies
A Chinese biotech that made a name for itself by co-developing an anti-Covid drug has filed for a stock market listing to fund research into tackling other conditions Key Takeaways:…
Kintor shares plunge after hair-loss drug flops in clinical trials
The company’s drug has failed to show a significant hair-boosting effect in Phase III trials, dashing investors’ hopes for a ground-breaking treatment for baldness Key Takeaways: The disappointing test results…
Booster Shot for Brii Biosciences with First Covid Drug Launch
Brii Biosciences announced the commercial launch of its injectable Covid antibody treatment, which will be covered by government medical insurance in many parts of the country Key Takeaways: The antibody…
Could Covid Drugs Help Cure Financial Ills at Ascletis Pharma?
Ascletis Pharma has applied for U.S. FDA approval to start clinical trials on a new Covid drug, ASC10 Key Takeaways: Ascletis Pharma is ready to put its new Covid drug…
FAST NEWS: Junshi Biosciences Oral Covid Drug Wraps Up Trials, to Seek Sales Approval
The latest: Drug developer Shanghai Junshi Biosciences Co. Ltd. (1877.HK; 688180.SH) announced late Monday that VV116, an oral drug developed by its JunTop Biosciences unit for the early treatment of Covid-19, has reached the main endpoint…
Recent Articles
RECENT ARTICLES
-
Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
-
BeiGene heads for profit milestone after hemorrhaging cash
6160.HK ONC.US 688235.SHG
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
- Innogen Pharma jostles for a slice of the weight-loss market
